Refine by
Microbiome Research Articles & Analysis
48 news found
"We are thrilled to introduce Long Amplicon Analysis to the genomics research community," stated the Market Director of CD Genomics. "LAA breaks through traditional sequencing constraints, empowering researchers with invaluable insights into the most intricate areas of the genome, accelerating their research and making significant contributions ...
The product manager is pleased to announce the launch of its Microbial Biomarker Discovery service, a revolutionary solution that promises to transform microbiology research. Microbiome research has rapidly gained momentum in recent years as scientists have come to appreciate the vital role that microbial communities play in maintaining human ...
Bened Biomedical Co, LTD., the global leader in psychobiotics with clinical studies, has acquired its US distributor Oryx Biomedical, Inc., who is pioneering the translation of microbiome research into impactful biotherapeutics and is one of the earliest stage companies bringing the gut-brain axis category of probiotics to the market. ...
We are investing in the next phase of microbiome health: post-discovery development and commercialization that will efficiently bring products to ...
Funds to support scale-up, including continued development of AI-augmented knowledge discovery platform, the e[datascientist]™, and continued international expansion Platform business focused on bridging the current ‘translation gap’, addressing critical bottlenecks in the industrial application of microbiome science – from soil, to plant, to farm, to fork, to human, ...
Today, Eagle Genomics, the software platform business pioneering the application of network science to biology,?announced its attendance at international tradeshow ACHEMA 2022 in Frankfurt, Germany next week (22-26 August) as a Microsoft Showcase Partner. Eagle Genomics will be featured in Microsoft’s ‘Digital Hub’ Innovation space under the theme “Eagle Genomics and ...
A surge in research projects on the human microbiome - the complex ecosystem of microorganisms in the human gastrointestinal tract - is bolstering scientific understanding of health, disease and environment. Much of the research has focused on gut bacteria and viruses, leaving a third factor - fungi - little studied. ...
The Microbiome Therapeutics Innovation Group (MTIG) today announced the addition of Bio-Me to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products. Bio-Me offers a wide range of proprietary solutions to facilitate the gut ...
ByBio-Me
The pipeline of Aptorum is also enriched through (i) the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases; and (ii) the co-development of a novel molecular-based rapid ...
As important will be the close collaboration with the Foundation, which has developed a unique set of resources to accelerate IBD research, such as clinical research networks and IBD Plexus®. MB310 is a fully defined LBT comprising 10 bacterial species, identified using Microbiotica’s unique microbiome discovery platform in combination ...
(California, USA) to work on microbial fermentation and novel prebiotics to modulate the human gut microbiome. Microviable expertise on gut microbiome research will enable to conveniently process microbiota samples for fermentation applications that coupled with BCD Bioscience advance prebiotics platform will open new avenues into human health ...
Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and biomarkers, today announced the completion of a £50 million ($67 million) Series B financing round – the largest microbiome-related financing in Europe to date. ...
City of Hope, one of the largest cancer research and treatment organizations in the United States, and Osel Inc., a company developing live biotherapeutic products for modulation of the human microbiome, today announced Phase 1 trial data showing that use of the live biotherapeutic CBM588 (Clostridium butyricum MIYAIRI 588® strain) plus immunotherapy medicine ...
Microbiome-based ingredient company Synbiotic Health announces that Kevin Hooper has joined the company as Director of Business Development. ...
Microbiome-based ingredient company Synbiotic Health is pleased to announce the appointment of Erin Vyhlidal as Controller and Vice President, Corporate Finance. ...
CD Genomics is a leading services company committed to providing global customers with the most comprehensive analytic services, including a broad range of microbial genomic solutions to support research and development. The company announced microbiome profiling services, alongside bioinformatic analysis technology to help researchers understand ...
Bancke, PharmD, Head of Clinical Development at Rebiotix, who presented the research. “They reinforce the enormous potential of microbiome-based therapeutics to transform the care of people suffering from ...
SMRT-based transcriptomics can be used to solve various research problems such as early embryo development, phylogenetic inference, cell differentiation, biomarker discovery, drug target identification, etc. ...
Analysis of data from five RBX2660 prospective studies is one of only four abstracts to receive the coveted IDWeek 2021 Program Committee Choice award for outstanding scientific research. Ferring and Rebiotix will present new data showing an association between clinical outcomes and restoration of the microbiome Research from the Phase 3 ...
On September 22nd Warren Flood, Ph.D. and COO of Bio-Me, will participate in a webinar organized together with Thermo Fisher Scientific with the title “Missing a piece of the puzzle? Factor in the gut microbiome”. There, he will present how our PMP platform, based on Thermo Fisher Scientific’s OpenArray qPCR technology, helps researchers and ...
ByBio-Me